The Chicago Entrepreneur

GeoVax’s stock soars 54% to lead rally in companies developing mpox treatments

A competing company’s mpox vaccine failed to meet its primary endpoint.

Previous post Estée Lauder’s stock falls on weak outlook due to China declines
Next post Inflation is on the way out, but high prices make life seem ‘unaffordable’